AmerisourceBergen

It seems that when it comes to Aranesp, its blockbuster anemia drug, Amgen (AMGN) just can't catch a break, nor for that matter, create one. Recently, Amgen was hit with a double whammy -- a lawsuit and an unfavorable study of the drug. On Tuesday, yet another study confirmed that cancer patients...